Company Description
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and develops pharmaceutical products in the United States and internationally.
Its lead product is AN8025, a tri-functional fusion protein of αPD-L1 x CD86 variant x LAG3 variant, a T-cell and antigen-presenting cell modulator, which is in phase 1a clinical trials for the treatment of tumor.
The company also developing AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers include pancreatic, lung, and colorectal adenocarcinomas; and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, which is in phase 1b treatment for tumor to activate cancer immunity.
It is also developing AN0025, a small molecule EP4 antagonist, which is in phase 1b clinical trials for the treatment of locally advanced esophageal cancer (+chemoradiation therapy), and radiotherapy which is in phase 2 clinical trials for the treatment of rectal cancer (+chemoradiation therapy).
Adlai Nortye Ltd. was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
| Country | Cayman Islands |
| Founded | 2004 |
| IPO Date | Sep 29, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 109 |
| CEO | Yang Lu |
Contact Details
Address: Ugland House, PO Box 309 Grand Cayman, KY1-1104 Cayman Islands | |
| Phone | 848 230 7430 |
| Website | adlainortye.com |
Stock Details
| Ticker Symbol | ANL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $23.00 |
| CIK Code | 1944552 |
| CUSIP Number | 00704R109 |
| ISIN Number | US00704R1095 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Yang Lu | Co- Founder, Chief Executive Officer and Chairman |
| Dr. Ngai Chiu Tse M.D., Ph.D. | President and Head of Research & Development |
| Dr. Xiaofeng Ye Ph.D. | Chief Financial Officer |
| Dr. Zhiyong Yu Ph.D. | Vice President of Operations |
| Chen Yang | Head of Human Resources and Administration & Government Affairs |
| Donghui Yang | Chairman of the Greater China Region |
| Dr. Nanhai He Ph.D. | Head of Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2026 | F-3/A | Filing |
| Apr 23, 2026 | F-3/A | Filing |
| Apr 16, 2026 | 6-K | Report of foreign issuer |
| Apr 10, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Apr 1, 2026 | 6-K | Report of foreign issuer |
| Mar 10, 2026 | F-3 | Filing |
| Feb 12, 2026 | 6-K | Report of foreign issuer |
| Feb 11, 2026 | SCHEDULE 13G | Filing |
| Feb 9, 2026 | SCHEDULE 13G/A | Filing |
| Feb 3, 2026 | 6-K | Report of foreign issuer |